Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Johnson & Johnson's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $650.6B | |
|---|---|---|
| Revenue (ttm) | 99.3B | |
| Net income (ttm) | 16.1B | |
| EPS (ttm) | $6.58 | |
| Shares out | 2.4B | |
| P/E (trailing) | 41.2x | |
| P/E (forward) | 21.1x | |
| Dividend | $5.36 (1.98%) | |
| Volume | 4,879,063 | |
| Beta | 0.21 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B | +4.6% |
| Gross profit | $55.34B | $55.39B | $58.61B | $61.35B | $63.94B | +3.7% |
| Operating income | $19.36B | $19.64B | $21.85B | $17.44B | $33.55B | +14.7% |
| Net income | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B | +6.4% |
| EPS (diluted) | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 | +9.0% |
| EBITDA | $26.75B | $26.61B | $29.34B | $24.78B | $41.06B | +11.3% |
| R&D | $0 | $0 | $483.0M | $1.84B | $109.0M | — |
| SG&A | $20.12B | $20.25B | $21.51B | $22.87B | $23.68B | +4.2% |
Recent company headlines from major financial publishers.
The Base case reflects our modal underwriting expectation, where disciplined commercial execution in Innovative Medicine balances anticipated loss-of-exclusivity patent expirations. Steady procedure growth across MedTech hospital ecosystems and stable geographic demand across Europe and Asia support steady cash flow compounding. Intrinsic value reaches Fair value $345.55, representing an upside of 28.0% from $269.99 (as of 2026-09-18) with an expected return of 28.0% at a assigned probability of 60.0%.
The Bull case envisions accelerated biopharmaceutical commercial adoption and expanding MedTech procedure volumes. In this outcome, newly launched therapeutics capture leading market share across immunology and oncology indications, while surgical robotics platforms achieve timely regulatory clearances and hospital integration. Consolidated revenue growth outpaces baseline expectations and operating margins expand, driving the valuation target to Potential value $530.18 with an implied return of 96.4% at an estimated likelihood of 20.0%.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.3% | $468 | $524 | $624 | $904 | $778 |
| 6.3% | $372 | $397 | $430 | $481 | $571 |
| 7.3% | $316 | $329 | $346 | $367 | $397 |
| 8.3% | $278 | $286 | $296 | $307 | $322 |
| 9.3% | $251 | $256 | $262 | $269 | $277 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
